Clinical epidemiology of pulmonary aspergillosis in hospitalized patients and contribution of Cyp51A, Yap1, and Cdr1B mutations to voriconazole resistance in etiologic Aspergillus species
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Pulmonary aspergillosis is a life-threatening fungal infection with worldwide distribution. In the present study, clinical epidemiology of pulmonary aspergillosis and antifungal susceptibility of etiologic Aspergillus species were evaluated in one-hundred fifty patients with special focus on the frequency of voriconazole resistance. All the cases were confirmed by the clinical pictures, laboratory findings, and isolation of etiologic Aspergillus species which belonged to two major species, i.e., A. flavus and A. fumigatus. Seventeen isolates displayed voriconazole MIC greater than or equal to the epidemiological cutoff value. Expression of cyp51A, Cdr1B, and Yap1 genes was analyzed in voriconazole-intermediate/resistant isolates. In A. flavus, Cyp51A protein sequencing showed the substitutions T335A and D282E. In the Yap1 gene, A78C replacement led to Q26H amino acid substitution that was not reported previously in A. flavus resistant to voriconazole. No mutations associated with voriconazole resistance were found in the three genes of A. fumigatus. The expression of Yap1 was higher than that of two other genes in both A. flavus and A. fumigatus. Overall, voriconazole-resistant strains of both A. fumigatus and A. flavus demonstrated overexpression of Cdr1B, Cyp51A, and Yap1 genes compared to voriconazole-susceptible strains. Although there are still ambiguous points about the mechanisms of azole resistance, our results showed that mutations were not present in majority of resistant and intermediate isolates, while all of these isolates showed overexpression in all three genes studied. As a conclusion, it seems that the main reason of the emergence of mutation in voriconazole-resistant isolates of A. flavus and A. fumigatus is previous or prolonged exposure to azoles.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
---|---|
Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 42(2023), 7 vom: 04. Juli, Seite 853-864 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Salehi, Zahra [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 06.07.2023 Date Revised 06.07.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10096-023-04608-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356460487 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM356460487 | ||
003 | DE-627 | ||
005 | 20231226070517.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10096-023-04608-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1188.xml |
035 | |a (DE-627)NLM356460487 | ||
035 | |a (NLM)37142789 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Salehi, Zahra |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical epidemiology of pulmonary aspergillosis in hospitalized patients and contribution of Cyp51A, Yap1, and Cdr1B mutations to voriconazole resistance in etiologic Aspergillus species |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 06.07.2023 | ||
500 | |a Date Revised 06.07.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
520 | |a Pulmonary aspergillosis is a life-threatening fungal infection with worldwide distribution. In the present study, clinical epidemiology of pulmonary aspergillosis and antifungal susceptibility of etiologic Aspergillus species were evaluated in one-hundred fifty patients with special focus on the frequency of voriconazole resistance. All the cases were confirmed by the clinical pictures, laboratory findings, and isolation of etiologic Aspergillus species which belonged to two major species, i.e., A. flavus and A. fumigatus. Seventeen isolates displayed voriconazole MIC greater than or equal to the epidemiological cutoff value. Expression of cyp51A, Cdr1B, and Yap1 genes was analyzed in voriconazole-intermediate/resistant isolates. In A. flavus, Cyp51A protein sequencing showed the substitutions T335A and D282E. In the Yap1 gene, A78C replacement led to Q26H amino acid substitution that was not reported previously in A. flavus resistant to voriconazole. No mutations associated with voriconazole resistance were found in the three genes of A. fumigatus. The expression of Yap1 was higher than that of two other genes in both A. flavus and A. fumigatus. Overall, voriconazole-resistant strains of both A. fumigatus and A. flavus demonstrated overexpression of Cdr1B, Cyp51A, and Yap1 genes compared to voriconazole-susceptible strains. Although there are still ambiguous points about the mechanisms of azole resistance, our results showed that mutations were not present in majority of resistant and intermediate isolates, while all of these isolates showed overexpression in all three genes studied. As a conclusion, it seems that the main reason of the emergence of mutation in voriconazole-resistant isolates of A. flavus and A. fumigatus is previous or prolonged exposure to azoles | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Antifungal susceptibility | |
650 | 4 | |a Aspergillus species | |
650 | 4 | |a Gene mutation | |
650 | 4 | |a Overexpression | |
650 | 4 | |a Pulmonary aspergillosis | |
650 | 4 | |a Voriconazole resistance | |
650 | 7 | |a Antifungal Agents |2 NLM | |
650 | 7 | |a Azoles |2 NLM | |
650 | 7 | |a Fungal Proteins |2 NLM | |
650 | 7 | |a Voriconazole |2 NLM | |
650 | 7 | |a JFU09I87TR |2 NLM | |
700 | 1 | |a Sharifynia, Somayeh |e verfasserin |4 aut | |
700 | 1 | |a Jamzivar, Fatemehsadat |e verfasserin |4 aut | |
700 | 1 | |a Shams-Ghahfarokhi, Masoomeh |e verfasserin |4 aut | |
700 | 1 | |a Poorabdollah, Mihan |e verfasserin |4 aut | |
700 | 1 | |a Abtahian, Zahra |e verfasserin |4 aut | |
700 | 1 | |a Nasiri, Naser |e verfasserin |4 aut | |
700 | 1 | |a Marjani, Majid |e verfasserin |4 aut | |
700 | 1 | |a Moniri, Afshin |e verfasserin |4 aut | |
700 | 1 | |a Salehi, Mohammadreza |e verfasserin |4 aut | |
700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
700 | 1 | |a Razzaghi-Abyaneh, Mehdi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 42(2023), 7 vom: 04. Juli, Seite 853-864 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
773 | 1 | 8 | |g volume:42 |g year:2023 |g number:7 |g day:04 |g month:07 |g pages:853-864 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-023-04608-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 42 |j 2023 |e 7 |b 04 |c 07 |h 853-864 |